Zotarolimus Eluting Stent use in small coronary vessels (≤2.5mm) results in similar 12-month clinical outcomes compared to Sirolimus and Paclitaxel eluting stents

Ronen Gurvitch,W M Wilson,M. Watts,J. Lefkovits,Roderic Warren,R. Iyer,Angela L Brennan,Nick Andrianopoulos,Christopher M Reid,Andrew E Ajani

Heart, Lung and Circulation（2009）

引用 0|浏览17

暂无评分

摘要

Background: The Zotarolimus Eluting Stent (ZES) has greater late loss compared to Sirolimus and Paclitaxel eluting stents (SES and PES). Hence, there is concern regarding higher subsequent revascularisation needs especially in small vessels.

查看译文

关键词

small coronary vessels,clinical outcomes,paclitaxel,sirolimus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要